© 2022 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr Shaji Kumar and Dr Jonathan Kaufman discuss the evolving role of biomarkers in multiple myeloma.
August 10th 2022
Jonathan Kaufman, MD, provides an overview of multiple myeloma (MM) and reviews current biomarkers and molecular pathways commonly seen in MM.
Dr Shaji Kumar explains the role of t(11;14) translocation in patients with multiple myeloma and discusses treatment options for this specific population.
August 18th 2022
Drs Shaji Kumar and Jonathan Kaufman review the BELLINI trial, as well as provide an overview of other investigational studies of BCL2 inhibitors for the treatment of patients with t(11;14) translocation with relapsed refractory multiple myeloma.
Shaji Kumar, MD, talks about new biomarkers that are being explored in patients with multiple myeloma.
August 24th 2022
Two experts review strategies and barriers to overcome for biomarker testing in patients with multiple myeloma.
Shaji Kumar, MD and Jonathan Kaufman, MD, discuss unmet needs in the multiple myeloma treatment landscape and share their insights on testing for biomarkers.